Immunome (IMNM) Q2 Revenue Surges 382%

Immunome (NASDAQ:IMNM), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantial revenue beat, with $4.0 million in GAAP revenue topping analyst forecasts by a wide margin, plus a narrower-than-expected GAAP loss per share. GAAP revenue was well ahead of consensus. Overall, the period reflected significant cash investment and pipeline activity, but also highlighted the absence of commercial-stage products. Source: Analyst estimates for the quarter provided by FactSet. Immunome is focused on discovering and developing new targeted cancer treatments. The approach combines antibody-drug conjugates (ADCs)—targeted cancer drugs that deliver chemotherapy directly to cancer cells—and other modalities. The pipeline includes several investigational medicines, such as varegacestat for desmoid tumors, IM-1021 for solid tumors and blood cancers, and preclinical ADC candidates for various cancer types.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool